|
Jun 25
|
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
|
|
Jun 25
|
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
|
|
Jun 11
|
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
|
|
May 28
|
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
|
|
Mar 12
|
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
|
|
Aug 1
|
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
|
|
Jul 31
|
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
|
|
Jul 25
|
Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
|
|
May 30
|
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
|
|
May 12
|
13 Penny Stocks with Insider Buying in 2024
|
|
May 10
|
Insider Spends US$1m Buying More Shares In Corvus Pharmaceuticals
|
|
May 7
|
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript
|
|
May 7
|
Q1 2024 Corvus Pharmaceuticals Inc Earnings Call
|
|
May 7
|
Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 6
|
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
|
|
May 2
|
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
|
|
May 2
|
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
|
|
Apr 17
|
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
|
|
Apr 9
|
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
|
|
Apr 1
|
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
|